Skip to main content
Client Work

Radiant Biotherapeutics secured USD $35 million Series A financing

Fasken
Reading Time 1 minute read
Share
  • LinkedIn

Overview

Client

Amplitude Ventures

Radiant Biotherapeutics (“Radiant”) secures $35 million in Series A financing.

The round was co-led by Amplitude Ventures and the Bill & Melinda Gates Foundation, both of whom share Radiant's vision of providing powerful, multifunctional biologics that can advance treatments for patients suffering from debilitating and life-threatening diseases.

Several other investors, including BDC Capital, FACIT, Alexandria Venture Investments, and Toronto Innovation Acceleration Partners (TIAP), participated in the Series A round.

The funds will enable Radiant to further develop its new multivalent, multispecific antibody platform, Multabody™, and advance it into clinical trials.

A Fasken team composed of Jonathan Raizenne, Guillaume Synnott and Dalia Tullio advised Amplitude Ventures in this funding.

Team

  • Jonathan Raizenne, Associate | Mergers & Acquisitions, Montréal, QC, +1 514 397 4394, jraizenne@fasken.com
  • Guillaume Synnott, Partner | Corporate/Commercial, Montréal, QC, +1 514 397 4325, gsynnott@fasken.com
  • Dalia Tullio, Associate | Corporate/Commercial, Montréal, QC, +1 514 397 5115, dtullio@fasken.com